Amphastar Pharmaceuticals Inc
AMPH27.640USD
+0.200+0.73%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
1.29BMarket Cap
9.54P/E TTM
More Details of Amphastar Pharmaceuticals Inc Company
Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically challenging generic and injectable, inhalation, and intranasal products. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. Its segments include finished pharmaceutical products and API products. The finished pharmaceutical products segment manufactures, markets and distributes Primatene MIST, epinephrine, glucagon, phytonadione, lidocaine, enoxaparin, naloxone, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes RHI API and porcine insulin API for external customers and internal product development. Its pipeline has over 20 product candidates, including generic ANDAs, biosimilar, and others.
Company Info
Ticker SymbolAMPH
Company nameAmphastar Pharmaceuticals Inc
IPO dateJun 25, 2014
CEODr. Yongfeng (Jack) Zhang, Ph.D.
Number of employees2028
Security typeOrdinary Share
Fiscal year-endJun 25
Address11570 6th St
CityRANCHO CUCAMONGA
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code91730
Phone19099809484
Websitehttps://amphastar.com/
Ticker SymbolAMPH
IPO dateJun 25, 2014
CEODr. Yongfeng (Jack) Zhang, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Rong Zhou
Mr. Rong Zhou
Senior Executive Vice President of Production Center, Executive Vice President of Scientific Affairs, President of Amphastar Nanjing Pharmaceuticals, Co., Ltd.
Senior Executive Vice President of Production Center, Executive Vice President of Scientific Affairs, President of Amphastar Nanjing Pharmaceuticals, Co., Ltd.
197.10K
+5.69%
Dr. Howard S. Lee, Ph.D.
Dr. Howard S. Lee, Ph.D.
Independent Director
Independent Director
148.90K
+2.90%
Mr. Floyd F. Petersen
Mr. Floyd F. Petersen
Independent Director
Independent Director
73.45K
-0.68%
Mr. William J. Peters
Mr. William J. Peters
Chief Financial Officer, Executive Vice President - Finance, Treasurer, President of International Medication Systems Limited, Director
Chief Financial Officer, Executive Vice President - Finance, Treasurer, President of International Medication Systems Limited, Director
55.44K
-0.49%
Mr. Richard K. Prins
Mr. Richard K. Prins
Lead Independent Director
Lead Independent Director
32.11K
+18.98%
Ms. Gayle Deflin
Ms. Gayle Deflin
Independent Director
Independent Director
7.84K
+188.59%
Mr. Jacob Liawatidewi
Mr. Jacob Liawatidewi
Executive Vice President of Sales and Marketing, Corporate Administration Center, President of Amphastar France Pharmaceuticals, S.A.S, Company Secretary, Director
Executive Vice President of Sales and Marketing, Corporate Administration Center, President of Amphastar France Pharmaceuticals, S.A.S, Company Secretary, Director
--
--
Mr. Dan Dischner
Mr. Dan Dischner
Vice President - Corporate Communications
Vice President - Corporate Communications
--
--
Ms. Diane G. Gerst
Ms. Diane G. Gerst
Independent Director
Independent Director
--
--
Mr. David Gaugh
Mr. David Gaugh
Director
Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Rong Zhou
Mr. Rong Zhou
Senior Executive Vice President of Production Center, Executive Vice President of Scientific Affairs, President of Amphastar Nanjing Pharmaceuticals, Co., Ltd.
Senior Executive Vice President of Production Center, Executive Vice President of Scientific Affairs, President of Amphastar Nanjing Pharmaceuticals, Co., Ltd.
197.10K
+5.69%
Dr. Howard S. Lee, Ph.D.
Dr. Howard S. Lee, Ph.D.
Independent Director
Independent Director
148.90K
+2.90%
Mr. Floyd F. Petersen
Mr. Floyd F. Petersen
Independent Director
Independent Director
73.45K
-0.68%
Mr. William J. Peters
Mr. William J. Peters
Chief Financial Officer, Executive Vice President - Finance, Treasurer, President of International Medication Systems Limited, Director
Chief Financial Officer, Executive Vice President - Finance, Treasurer, President of International Medication Systems Limited, Director
55.44K
-0.49%
Mr. Richard K. Prins
Mr. Richard K. Prins
Lead Independent Director
Lead Independent Director
32.11K
+18.98%
Ms. Gayle Deflin
Ms. Gayle Deflin
Independent Director
Independent Director
7.84K
+188.59%
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
No Data
By RegionUSD
Name
Revenue
Proportion
United States
162.59M
95.35%
France
7.86M
4.61%
China
81.00K
0.05%
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, Aug 15
Updated: Fri, Aug 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Applied Physics & Chemistry Laboratories, Inc.
14.68%
BlackRock Institutional Trust Company, N.A.
11.02%
The Vanguard Group, Inc.
5.73%
Zhang (Jack Yongfeng)
5.64%
TD Asset Management Inc.
4.38%
Other
58.54%
Shareholders
Shareholders
Proportion
Applied Physics & Chemistry Laboratories, Inc.
14.68%
BlackRock Institutional Trust Company, N.A.
11.02%
The Vanguard Group, Inc.
5.73%
Zhang (Jack Yongfeng)
5.64%
TD Asset Management Inc.
4.38%
Other
58.54%
Shareholder Types
Shareholders
Proportion
Investment Advisor
40.40%
Investment Advisor/Hedge Fund
20.53%
Corporation
14.68%
Individual Investor
9.33%
Hedge Fund
7.36%
Research Firm
2.22%
Pension Fund
0.93%
Bank and Trust
0.33%
Sovereign Wealth Fund
0.11%
Other
4.10%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
602
45.09M
95.69%
-4.23M
2025Q1
611
45.81M
97.08%
-3.30M
2024Q4
605
46.57M
97.74%
-2.04M
2024Q3
587
46.65M
96.28%
-609.11K
2024Q2
577
45.56M
93.11%
-1.23M
2024Q1
560
44.76M
91.63%
-1.31M
2023Q4
542
44.44M
92.40%
-767.71K
2023Q3
510
43.50M
90.64%
-1.16M
2023Q2
483
43.02M
88.37%
-388.11K
2023Q1
456
42.07M
87.29%
-710.60K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Applied Physics & Chemistry Laboratories, Inc.
6.83M
14.48%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
5.52M
11.72%
-66.62K
-1.19%
Mar 31, 2025
The Vanguard Group, Inc.
2.41M
5.12%
-291.72K
-10.78%
Mar 31, 2025
Zhang (Jack Yongfeng)
2.62M
5.57%
+200.00K
+8.25%
Jun 13, 2025
TD Asset Management Inc.
2.21M
4.69%
+371.86K
+20.21%
Mar 31, 2025
Dimensional Fund Advisors, L.P.
1.36M
2.88%
+157.77K
+13.16%
Mar 31, 2025
State Street Global Advisors (US)
1.60M
3.4%
+8.50K
+0.53%
Mar 31, 2025
Fuller & Thaler Asset Management Inc.
1.26M
2.68%
+130.67K
+11.53%
Mar 31, 2025
Epoch Investment Partners, Inc.
1.26M
2.68%
+160.03K
+14.53%
Mar 31, 2025
Boston Trust Walden Company
1.22M
2.58%
+236.70K
+24.18%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Sep 6
Updated: Sat, Sep 6
Name
Proportion
Acquirers Small and Micro Deep Value ETF
0%
Global X Russell 2000 Covered Call ETF
0%
Invesco S&P SmallCap 600 QVM Multi-factor ETF
0%
DFA Dimensional US Core Equity Market ETF
0%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
0%
ETC 6 Meridian Low Beta Equity Strategy ETF
0%
ETC 6 Meridian Small Cap Equity ETF
0%
Zacks Small/Mid Cap ETF
0%
Vanguard ESG U.S. Stock ETF
0%
Fidelity Nasdaq Composite Index ETF
0%
View more
Acquirers Small and Micro Deep Value ETF
Proportion0%
Global X Russell 2000 Covered Call ETF
Proportion0%
Invesco S&P SmallCap 600 QVM Multi-factor ETF
Proportion0%
DFA Dimensional US Core Equity Market ETF
Proportion0%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion0%
ETC 6 Meridian Low Beta Equity Strategy ETF
Proportion0%
ETC 6 Meridian Small Cap Equity ETF
Proportion0%
Zacks Small/Mid Cap ETF
Proportion0%
Vanguard ESG U.S. Stock ETF
Proportion0%
Fidelity Nasdaq Composite Index ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
